Skip to main content
Caplight Logo









Mabylon AG

Mabylon AG

Private
SchlierenHealthcare & Life Scienceshttps://www.mabylon.com/

Last Round

VC Round

Aug 12, 2025

Total Funding Raised

$1.48M

Momentum

Top 50%

of companies Caplight tracks

Company Overview

Mabylon AG is a biotechnology company that discovers and develops human-derived antibody therapeutics for the treatment of allergies, inflammation, and neurodegenerative diseases.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Clinical Trials

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

biotechnologyantibody therapeuticsdrug discoverymonoclonal antibodiesmulti-specific antibodiesb-cell screeningbiotechclinical-stage biotechallergy treatmentneurodegenerative disease researchbiopharmatherapeutic pipelinedrug developmentclinical trialsbiotech startup

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Mabylon AG Comparables

Compare Mabylon AG with similar companies based on industry and business-model similarity.

Mabylon AG comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
IgGenix
85%
Dualitas Therapeutics
78%
Poplar Therapeutics
77%

Mabylon AG Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
VC RoundAug 12, 2025
GrantSep 24, 2024

Key People

Founding team and executive leadership

Alcide Barberis

CEO and Director

Executive Team

Tiziana Sonati

Chief Operating Officer

Executive Team

Mabylon AG Investors

Notable investors and investment history

Mabylon AG investors
InvestorRounds
The ALS AssociationGrant
NIH RADxGrant
Eurostars SME programmeGrant
Target ALSGrant
InnosuisseGrant

Market signals

Structured signals derived from secondary market and firmographic data.

  • May 11, 2026

    Monthly visitors increased 151% MoM.

  • Apr 21, 2026

    Monthly visitors grew 217% MoM, reaching 606.

Mabylon AG Filings

Explore SEC and related filing metadata, where available.

Mabylon AG filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about Mabylon AG's valuation, stock price, and market status.

Is Mabylon AG a public or private company?

Mabylon AG is a private company.

What is the current stock price of Mabylon AG?

Mabylon AG is a private company with no public stock price. No recent secondary market data is available.

How much is Mabylon AG worth (valuation)?

Valuation information for Mabylon AG is not publicly available.

Can I buy Mabylon AG stock?

Mabylon AG shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was Mabylon AG's last funding round?

Mabylon AG's most recent funding round was VC Round on August 12, 2025.

Who are the main investors in Mabylon AG?

Key investors in Mabylon AG include The ALS Association, NIH RADx, Eurostars SME programme, Target ALS, Innosuisse.

Will Mabylon AG IPO soon?

No public IPO plans have been announced for Mabylon AG.

How can I track Mabylon AG secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Mabylon AG's secondary market activity and sign up for updates.

Firmographic Details

HeadquartersSchlieren
Employee Range19
Year Founded2015
Last FundingAug 12, 2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?